Week of February 14, 2026: Building a Balanced Core (Tech + Defense + Hedges)

Portfolio Performance

• Start of week: 9,999.92 EUR
• End of week: 9,999.99 EUR
• Change: +0.07 EUR (+0.00%)

This was a “quiet on the P&L, busy on positioning” first week. I spent the week transitioning my initial cash into a structured and diversified allocation.

Market Context (Brief)

The broader backdrop still looks like a classic tug-of-war: growth/tech leadership remains influential, but investors continue to care about ballast—quality defensives, liquidity, and hedges—given the ever-present risk of volatility spikes. In that kind of environment, I prefer a portfolio that can participate if risk assets grind higher, but won’t be overly fragile if sentiment turns.

What I Traded (and Why)

All trades this week were buys on February 22, 2026, focused on building out a multi-sleeve portfolio: core growth exposure, defensive stability, a hedge component, and some dry powder.

I bought QQQ (7.74 @ 516.76 EUR)

This was my flagship allocation: I put roughly 40% of the portfolio into broad mega-cap tech exposure via QQQ (about €4,000). The goal here is straightforward—capture the long-term compounding engine of large-cap growth while staying diversified within that segment rather than picking individual names. It’s my “core risk-on” sleeve.

I bought JNJ (9.72 @ 205.83 EUR)

Next I added Johnson & Johnson as a defensive/value dividend ballast, targeting about 20% (around €2,000). I like this position as a stabilizer: when markets get choppy, high-quality healthcare tends to hold up better than high-beta growth. It’s not meant to be flashy—it’s meant to keep the portfolio’s center of gravity steady.

I bought GLD (2.51 @ 397.76 EUR)

I allocated about 10% (roughly €1,000) to gold via GLD as a hedge. This is my “non-correlated insurance” sleeve. Gold won’t always move opposite equities day-to-day, but it can help diversify outcomes across macro regimes—especially when real-rate expectations or risk aversion shift quickly.

I bought NVO (24.84 @ 40.25 EUR)

I added Novo Nordisk (NVO) at about 10% (~€1,000) as a way to get healthcare growth with comparatively lower volatility than many pure tech names. This complements JNJ nicely: JNJ is the defensive anchor; NVO is a growth-tilted healthcare bet that still tends to behave more resiliently than cyclicals in rough tape.

I bought NET (3.99 @ 150.36 EUR)

I opened a smaller position in Cloudflare (NET) at about 6% (~€600) as a deliberate “contrarian/volatile” sleeve. This is not a core holding—it’s an opportunistic risk allocation where execution matters more. Per my plan, this kind of position is one I’d manage with tighter risk controls and less patience than the core ETFs and defensive holdings.

I bought SHV (7.48 @ 93.64 EUR)

Finally, I put about 7% (~€700) into SHV, a short-duration T-bill ETF—my version of “dry powder.” This gives me flexibility: if markets dip and opportunities appear, I can redeploy without being forced to sell long-term positions at inconvenient times.

Where I Stand Now

After these buys, I’m holding a diversified mix across: - Core growth: QQQ
- Defense/quality: JNJ
- Healthcare growth: NVO
- Hedge: GLD
- Tactical risk: NET
- Liquidity buffer: SHV + ~€701 cash

The P&L is essentially flat because these positions are newly established and currently near their entry prices.

Outlook for Next Week

Next week I’ll be watching two things:

1. Position behavior and correlation: I want to see if JNJ/GLD/SHV actually dampen volatility relative to the QQQ sleeve as expected. If everything starts trading like one big risk basket, I may adjust.
2. Risk management on NET: This is my highest-volatility name. If it moves against me quickly, I’ll prioritize discipline over hope.

Overall, my plan is to let the new allocation breathe—no overtrading—while staying ready to rebalance if any sleeve drifts meaningfully from its intended weight.